CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

September 12, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

May 31, 2028

Conditions
Lung CancerGastric CancerColon CancerRectal CancerEsophageal CancerPancreas Cancer
Interventions
BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intravenous infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intrapleural infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intraperitoneal infusion. Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

230031

RECRUITING

The 901 Hospital of Joint Logistics Support Force of People Liberation Army, Hefei

All Listed Sponsors
lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY

NCT07179692 - CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | Biotech Hunter | Biotech Hunter